Table 5 Comparison of ORR and DCR in subgroup analysis.

From: 5-Fluorouracil combined with CalliSphere drug-eluting beads or conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score weighting analysis

 

M1

M3

M6

5-Fu-DEB-TACE

5-Fu-cTACE

p-Value

5-Fu-DEB-TACE

5-Fu-cTACE

p-Value

5-Fu-DEB-TACE

5-Fu-cTACE

p-Value

BCLC A

         

ORR

21(91.3%)

11(100%)

0.313

20(87%)

8(72.7%)

0.309

16(69.6%)

9(81.8%)

0.449

DCR

21(91.3%)

11(100%)

0.313

20(87%)

10(90.9%)

0.738

17(73.9%)

10(90.9%)

0.252

BCLC B

         

ORR

26(92.9%)

19(79.2%)

0.149

25(89.3%)

13(54.2%)

0.004

22(78.6%)

13(54.2%)

0.061

DCR

28(100%)

23(95.8%)

0.275

25(89.3%)

15(62.5%)

0.022

22(78.6%)

14(58.3%)

0.115

BCLC C

         

ORR

13(86.7%)

20(66.7%)

0.153

11(73.3%)

16(53.3%)

0.197

10(66.7%)

11(36.7%)

0.057

DCR

13(86.7%)

25(83.3%)

0.771

11(73.3%)

22(73.3%)

1.000

11(73.3%)

15(50%)

0.135

Child-pugh A

         

ORR

53(93%)

47(79.7%)

0.038

51(89.5%)

36(61%)

<0.001

45(78.9%)

32(54.2%)

0.005

DCR

53(93%)

53(89.8%)

0.545

51(89.5%)

43(72.9%)

0.023

47(82.5%)

38(64.4%)

0.028

Child-pugh B

         

ORR

7(77.8%)

3(50%)

0.264

5(55.6%)

1(16.7%)

0.132

3(33.3%)

1(16.7%)

0.475

DCR

9(100%)

6(100%)

-

5(55.6%)

4(66.7%)

0.667

3(33.3%)

1(16.7%)

0.475

ECOG 0

         

ORR

49(92.5%)

28(84.8%)

0.263

46(86.8%)

19(57.6%)

0.002

40(75.5%)

21(63.3%)

0.240

DCR

51(96.2%)

32(97%)

0.855

46(86.8%)

23(69.7%)

0.053

41(77.4%)

22(66.7%)

0.276

ECOG 1–2

         

ORR

11(84.6%)

22(68.8%)

0.275

10(76.9%)

18(56.3%)

0.195

8(61.5%)

12(37.5%)

0.141

DCR

11(84.6%)

27(84.4%)

0.984

10(76.9%)

24(75%)

0.892

9(69.2%)

17(53.1%)

0.321

Unifocal

         

ORR

31(93.9%)

29(78.4%)

0.063

30(90.9%)

22(59.5%)

0.003

27(81.8%)

19(51.4%)

0.007

DCR

33(100%)

33(89.3%)

0.052

30(90.9%)

28(75.7%)

0.091

28(84.8%)

23(62.2%)

0.033

Multifocal

         

ORR

29(87.9%)

21(75%)

0.192

26(78.8%)

15(53.6%)

0.037

21(63.6%)

14(50%)

0.283

DCR

29(87.9%)

26(92.9%)

0.515

26(78.8%)

19(67.9%)

0.333

22(66.7%)

16(57.1%)

0.444

Non-extrahepatic metastasis

         

ORR

56(90.3%)

42(79.2%)

0.095

53(85.5%)

31(58.5%)

0.001

45(72.6%)

28(52.8%)

0.028

DCR

58(93.5%)

50(94.3%)

0.172

53(85.5%)

39(73.6%)

0.112

47(75.8%)

34(64.2%)

0.172

Extrahepatic metastasis

         

ORR

4(100%)

8(66.7%)

0.182

3(75%)

6(50%)

0.383

3(75%)

5(41.7%)

0.248

DCR

4(100%)

9(75%)

0.267

3(75%)

8(66.7%)

0.755

3(75%)

5(41.7%)

0.248

Non-vascular Invasion

         

ORR

46(90.2%)

32(78%)

0.107

47(92.2%)

27(65.9%)

0.002

40(78.4%)

22(53.7%)

0.012

DCR

47(92.2%)

37(90.2%)

0.746

47(92.2%)

32(78%)

0.053

42(82.4%)

27(65.9%)

0.069

Vascular Invasion

         

ORR

14(93.3%)

18(75%)

0.147

9(60%)

10(41.7%)

0.265

8(53.3%)

11(45.8%)

0.648

DCR

15(100%)

22(91.7%)

0.251

9(60%)

15(62.5%)

0.876

8(53.3%)

12(50%)

0.839

Largest size <5 cm

         

ORR

11(100%)

14(82.4%)

0.140

9(81.8%)

12(70.6%)

0.503

7(63.6%)

11(64.7%)

0.954

DCR

11(100%)

15(88.2%)

0.238

9(81.8%)

14(82.4%)

0.971

8(72.7%)

14(82.4%)

0.544

Largest size ≥ 5 cm

         

ORR

49(89.1%)

36(75%)

0.060

47(85.5%)

25(52.1%)

<0.001

41(74.5%)

22(45.8%)

0.003

DCR

51(92.7%)

44(91.7%)

0.841

47(85.5%)

33(68.8%)

0.042

42(76.4%)

25(52.1%)

0.010

  1. P value < 0.05 was considered significant, and the significant results were shown in boldface. M1, 1 month; M3, 3 months; M6, 6 months; DEB-TACE, drug-eluting bead transarterial chemoembolization; cTACE, conventional transarterial chemo-embolization; 5-Fu, 5-Fluorouracil; ECOG, Eastern Oncology Group; BCLC, Barcelona Clinic Liver cancer; ORR, objective response rate; DCR, disease control rate.
Back to article page